Something cheerful to start the weekend

 
 
http://www.sciencedaily.com/releases/2012/08/120815174908.htm
 
every little step helps
 
 
 
Age 58
G9 (5+4)
12 of 12 cores positive, 100% involvement
Dx 5-2012 Metastatic PCa, lymph nodes & extensive bone mets

PSA 61.1 (5-2-2012) -- prior to any treatment
PSA 48.7 (5-29-2012) -- after casodex only
PSA 4.6 (6-11-2012) -- 11 days after 1st firmagon injection
PSA 0.15 (7-2012)
Least it talked about a 2 year extension, which is way more than the advertised 6 months for Provenge. Promising news.
Age: 60, 56 at PC dx, PSA 16.3
3rd Biopsy: 9/8 7 of 7 Positive, 40-90%, 4+3
open RP: 11/8, Catheter in 63 days
Path Rpt: 3+4, pT2c, 42g, 20% tumor, 1 pos margin
Incont & ED: None
Surgery Failed, recurrence within 9 months
Salvage Radiation 10/9-11/9, SRT failed within 9 months, PSA 4/12 = 37.x
Spent total of 1 ½ years on 21 catheters, Ileal Conduit Surgery 9/10,
7 other PC-related surgeries
Member of Prostate Cancer & Chronic Pain HW Communities since 10/2008
“I live in the weak and the wounded” – Session Nine (Movie)
Keep Fighting the beast!

Science and medicine are truly catching up!

I firmly believe that!

HUGS

Bud

We will beat this crap!
65 - April 2013
Gonna Make Myself A Better Man tinyurl.com/28e8qcg
12 Jul 11 - 1447 (It's just a number! )
Scans showed active prostate cancer widespread in bones
Started HT treatments and Zometa for bone
31 Oct 11 - 46.6 Cheers!
25 Jan 12 - 75 - Crap
22 Feb - 99 - Restarted Casodex
22 Mar - 149 - Start Zytiga
25 Apr - 113
22 May - 66
19 Jun - 38
19 Jul -34 - Still going down!
Not to rain on the parade but the median survival was lengthened by only 4.8 months about the same as Provenge. In another article I read on this the cost was about $6000 per month. Personally, I am not a fan of either drug. Extreme cost for relatively low benefit. Plus neither addresses what those additional months might be like in terms of QOL.
 
I guess I am just plain selfish in that I want a cure... not a treatment that prolongs suffering. (I know about what if the cure comes during the extension argument). I read an article some time back that stated that the majority of drugs developed and approved over the last ten years did not have curative intent at the root of the research and were primarily palliative in nature. Hmmm.
 
Don
Don -- I hear you. In the very dark days after my husband was first diagnosed, I was reading everything I could find, I found it more discouraging to get to the end of the section on "cutting edge treatment X" and find that it adds only a handful of months. But I've come around to thinking progress is progress, and I'll take our current imperfect solutions that only buy time, on the faith that in that bought time, another better solution will come along. Science can take smallish steps as long as it's a few steps ahead of us. Plus, some day one of those small steps will lead to the big breakthrough.

So I'll still take that "golden age" headline and focus on that.
Age 58
G9 (5+4)
12 of 12 cores positive, 100% involvement
Dx 5-2012 Metastatic PCa, lymph nodes & extensive bone mets

PSA 61.1 (5-2-2012) -- prior to any treatment
PSA 48.7 (5-29-2012) -- after casodex only
PSA 4.6 (6-11-2012) -- 11 days after 1st firmagon injection
PSA 0.15 (7-2012)
I also found the 4.3 months to be negligible until I really understood the types of groups of men involved in these studies. Someone here explained it very clearly. Simply, there are very, very sick men and others who are struggling for control of the disease. Many of the very, very sick are so far progressed or their cancer is so aggressive that any treatment administered at that point has little chance. But there's always the hope for a miracle in these types of treatments. But meanwhile, others in these groups who's disease is still late term but more treatable, last far longer after the Provenge-type treatments. In fact, someone mentioned here the other day, JohnT--- maybe, that there is a recent Provenge 5 year study that has just been released. The important things to remember are that there are very sick people and then others that are not as sick and their results are averaged. The men that DO survive after the treatment make it FAR longer than the 4.3 month average. In fact the jury is still out on how far they could make it.

I find these studies and new treatments remarkable AND profoundly encouraging. My G6 will hopefully never be treated again, but it is nice to know that more and more bullets are being put in the clip to fight this disease. My 5 month old son might never have to go thru what I did by time reaches an age where his prostate could cause him problems. For me, that's a soothing thought.
DUDE1969, you nailed it. YES, the point is that results are MEDIAN. In PROVENGE trial PLACEBO arm received FROZEN PROVENGE (crossover) from the beginning . IT was disadvantage for company. DENDREON compete against own product only in frozen condition. And still PROVENGE reach OS (overall surviver). No one other product ( ZYTIGA, MDV3100) was designed such way. Those data, demonstrated a median 4.1-month survival benefit. The actual median survival benefit may be as much as 7.8 to 12.1 months MEDIAN
When you break the data from the 512-patient study into subsets based on Baseline PSA, the results, in the words of the investigators, G. Chodak, et al., "…support a consistent overall survival, or OS, benefit with sipuleucel-T across PSA quartiles." As noted by the authors, in the IMPACT study (n=512), there was a 4.1-month improvement in median OS (25.8 vs. 21.7months) for sipuleucel-T compared with control (HR=0.78; 95% CI: 0.61, 0.98; p=0.032). Importantly, 109/171 (64%) of control patients received APC8015F( Frozen PROVENGE) "Post-progression treatment with APC8015F may have extended the survival of control subjects in the IMPACT study. Adjusting for use of APC8015F resulted in an increase in median OS benefit with sipuleucel-T of up to 7.8 months. These results suggest a greater treatment effect of sipuleucel-T than reported in IMPACT, and should be
factored into future studies without APC8015F crossover."(trials.)

You can see chart on this poster:

http://www.scribd.com/doc/73051542/ASCO-Poster-Prolonged-Survival-in-Control-Arm-Sip-T-Gomella-20111

Abstract for AUA2012:

http://www.aua2012.org/abstracts/process.cfm?title=Prostate+Cancer:+Advanced&searchType=title

Post Edited (Hopeneverdie) : 8/20/2012 9:00:40 AM (GMT-6)